No Data
On the first day, it surged 117%! ADC star company InnoCare Biotech-B (09606) listed on the Hong Kong Stock Exchange, setting a record for the highest increase in new stocks this year.
On April 15, antibody-drug conjugate (ADC) star company Igenbio-B (09606) was officially listed on the Main Board of the Hong Kong Stock Exchange.
Hong Kong Stocks Rise Slightly; Duality Biotherapeutics Soars 117% in Debut
Hong Kong stocks close | Under the shadow of tariffs, major indices performed unevenly. ZHOU HEI YA surged nearly 8%, leading the Consumer stocks to break through.
① How did Trump's tariff policy lead to a divergence in the Hong Kong stock market? ② Why does HTSC still recommend allocating to Hong Kong stock dividend direction despite tariff disruptions?
Duality Biotherapeutics Raises HK$1.5 Billion From BioNTech-backed Hong Kong IPO
Duality Biotherapeutics Shares Rise 118% in Hong Kong Debut
First day of the new stock | InnoCare Bio-B (09606) was officially listed, opening with a 91.33% increase in the morning. The company is a developer of Innovative Drugs for ADC.
Ying'en Biotechnology-B (09606) was listed for the first time, and the announcement shows that the price per share is HKD 94.6, with a total issuance of 17.3323 million shares, each lot consisting of 100 shares, and the net proceeds amounting to approximately HKD 1.513 billion. As of the time of writing, the stock has risen by 91.33%, trading at HKD 181, with a transaction volume of HKD 0.782 billion.
